Prescribing Aripiprazole

Why Aripiprazole Matters

Aripiprazole is the antipsychotic you reach for when you want dopamine coverage without the metabolic and prolactin baggage that made the second-generation agents infamous. It was the first dopamine partial agonist to reach the market, and that single mechanistic fact drives nearly everything useful about it: minimal weight gain, no meaningful hyperprolactinemia, low sedation, and a low burden of extrapyramidal side effects. Among the atypicals it sits with ziprasidone and lurasidone in the "metabolically clean" column, and unlike ziprasidone it does not meaningfully prolong the QT interval.

But it is important to separate what aripiprazole is good at from what its marketing once claimed. When it launched in 2002, the pitch was that a "dopamine stabilizer" would be mechanistically superior for psychosis and negative symptoms. It is not. In the pivotal Kane trial, aripiprazole 15 and 30 mg matched haloperidol 10 mg on both positive and negative symptoms, no better, no worse. Its edge over haloperidol was entirely tolerability, not efficacy. The old Carlat Report verdict captured it perfectly: "the most perfect atypical, but enough about its mechanism."

Part 1: Indications: Who Is Aripiprazole For?

FDA-Approved Uses

• Schizophrenia (acute and maintenance; adults and adolescents 13-17)
• Bipolar I disorder, acute manic and mixed episodes (monotherapy or adjunct to lithium/valproate; ages 10+)
• Bipolar I maintenance (monotherapy or adjunct)
• Adjunctive treatment of major depressive disorder, augmentation of an antidepressant in inadequate responders (the flagship "add-on" indication)
• Irritability associated with autism spectrum disorder (ages 6-17)
• Tourette's disorder (ages 6-18)

The Evidence-Based Clinical Uses

Schizophrenia, solid but not special. Aripiprazole is a legitimate first-line antipsychotic, but choose it for tolerability, not power. In the Kane trial (414 acutely relapsed patients), aripiprazole 15 mg and 30 mg equaled haloperidol 10 mg on positive and negative symptoms, differing only in a cleaner side-effect profile. Effect sizes across the atypicals are broadly similar (CATIE confirmed this); aripiprazole is not clozapine and is not the agent for treatment-resistant psychosis. Where it shines is the young, first-episode, metabolically vulnerable patient in whom you want to avoid weight gain, sedation, and prolactin elevation from day one.

MDD augmentation, the marquee indication, honestly appraised. This is where aripiprazole is used most in general psychiatry, and the data are genuinely positive but modest. Two FDA-registration RCTs (SSRI/venlafaxine non-responders randomized to adjunctive aripiprazole vs placebo) showed remission 25-26% vs 15-16%, about a 10% absolute advantage, NNT ~10. The catch: MADRS separated from placebo by only ~2.8 points in one trial, and patient-rated depression scales did not separate. The VAST-D trial (1,522 VA patients failing an antidepressant) gave the most clinically useful comparison: augmenting with aripiprazole produced 29% remission vs 22% for switching to bupropion (NNT ~10), with a higher response rate, but at a metabolic and akathisia cost.

Bipolar mania, a genuine strength. For acute mania, aripiprazole works well: meta-analysis shows ~50% response vs ~35% placebo, both as monotherapy and as adjunct when lithium or valproate alone falls short. This is one of its more robust efficacy signals.

Bipolar I maintenance, real, but read the fine print. FDA-approved on the strength of ~18-month relapse-prevention RCTs. Note the enriched design: only patients who had already responded acutely to aripiprazole were randomized. That inflates apparent maintenance efficacy and limits generalizability, the same statistical caveat that applies to lithium's and lamotrigine's maintenance approvals. It delays time to manic relapse more convincingly than depressive relapse.

Where Aripiprazole Underperforms: Know These Cold

• Bipolar depression (monotherapy): it does not work. Two acute trials and meta-analysis found aripiprazole no better than placebo for bipolar depression. It is not FDA-approved for this. Do not reach for it here, use quetiapine, lurasidone, lumateperone, or cariprazine, which have the data.
• The "happily-ever-after fallacy": the fact that aripiprazole maintains remission in bipolar I does not mean it treats acute bipolar depression. Prevention and acute treatment are pharmacologically different jobs.
• ADHD: the theory that dopamine partial agonism would help was tested and failed in two negative RCTs. Don't.

Off-Label Uses With Some Support

• Borderline personality disorder: among antipsychotics, aripiprazole has some of the more positive trial data for anger and cognitive-perceptual symptoms, modest, small studies.
• Bipolar II depression: post-hoc and open-label data suggest benefit specifically at low doses (≤5-10 mg/day), lower than the bipolar I mania range. Off-label; weigh carefully.
• OCD augmentation, Tourette's: low-dose antipsychotic augmentation has a role; risperidone is better studied for OCD, but aripiprazole is FDA-approved for Tourette's.

Part 2: Before You Start: Workup and Candidacy

Aripiprazole is metabolically gentle, so the workup is lighter than for olanzapine or quetiapine, but the metabolic baseline still matters, because any antipsychotic can shift glucose and lipids, and because your patient may later be switched to a dirtier agent you'll want to compare against.

Baseline Workup

Aripiprazole is one of the atypicals for which a screening ECG is not mandatory in a patient without cardiac history, because it does not meaningfully prolong the QT interval.

Who Is a Poor Candidate?

• Elderly patients with dementia-related psychosis: boxed warning; increased mortality (see Part 6).
• Akathisia-prone patients: anyone who developed intolerable restlessness on a prior antipsychotic is at high risk of a repeat; consider a lower-akathisia alternative (quetiapine) or commit to very slow titration plus prophylaxis.
• Patients who need acute sedation: aripiprazole is activating far more often than sedating; it is a poor choice when you need to calm an agitated patient quickly.
• Acute bipolar depression: wrong drug (see Part 1).

Part 3: How to Start and Dose

The single most important dosing principle: the right dose depends entirely on the indication, and lower is usually better. Depression augmentation lives at 2-5 mg. Psychosis and mania live at 10-30 mg. Getting this backwards, starting a depressed patient at 15 mg, is the most common way to generate needless akathisia.

Formulations

A digital pill version (Abilify MyCite, with an ingestible sensor) exists but sees little practical use.

Dosing by Indication

MDD augmentation (start low, this is the key):

• Start 2-2.5 mg once daily (halve a 5 mg tablet).
• Increase to 5 mg after ~5-7 days if tolerated and no early response.
• The evidence sweet spot is 2-5 mg. A 2022 meta-analysis found the odds ratio climbing from 2 mg (1.46) to 4 mg (1.87) to 5 mg (1.91), then plateauing: doses beyond 5 mg add tolerability cost without added benefit.
• Ceiling for augmentation: 10 mg. If no response at 10 mg after 2-4 weeks, switch strategies.
• Dose in the morning: stimulation outnumbers sedation roughly 2:1.

Schizophrenia:

• Start 10-15 mg once daily (15 mg is the usual effective starting and target dose).
• Range 10-30 mg/day; 30 mg is not more effective than 15 mg for most and brings more akathisia.
• In a first-episode or sensitive patient, starting at 5-10 mg and titrating up is reasonable to blunt akathisia.

Bipolar mania (mono or adjunct):

• Start 15 mg once daily, range 15-30 mg. Most trial patients did well at 15 mg.
• As adjunct to lithium/valproate for partial response: 15 mg is typical.

Bipolar II depression (off-label): if used at all, stay low (≤5-10 mg); higher doses were less effective in post-hoc analyses.

Autism irritability (ages 6-17): start 2 mg/day, titrate slowly to 5-15 mg based on response and tolerability.

Intellectual disability: start 2 mg for 1 week, then 5 mg for 1 week, with careful staff monitoring (higher NMS risk and fatality in this population).

Onset and Steady State

Aripiprazole has a long half-life (~75 hours; its active metabolite dehydro-aripiprazole ~94 hours), so steady state takes about 2 weeks. Two practical consequences: don't chase early non-response with rapid dose escalation, give each dose ~1-2 weeks; and the drug is slow to wash out, which is forgiving of a missed dose but unforgiving when a CYP inhibitor is added (see Part 7).

Part 4: Monitoring: The Schedule

Aripiprazole is a "metabolically clean" antipsychotic, so it earns the lighter of the two standard monitoring schedules. But lighter is not none: the boxed and class risks (metabolic drift, tardive dyskinesia) still require surveillance.

Act on These

• ≥5-7% weight gain from baseline in the first weeks: intervene early, lifestyle counseling and consider metformin started proactively (it works best begun early; see Part 5). Aripiprazole's weight liability is low but not zero, especially in the antipsychotic-naive.
• Any new involuntary movements on AIMS: document, consider dose reduction or switch, and discuss tardive dyskinesia (see Part 5). TD is not a benign afterthought here, the class rate is ~3.9%/year (~5%/year in the elderly).
• New/worsening restlessness: think akathisia first (see Part 5); it is the most likely and most treatable complaint.

Part 5: Side Effects and How to Manage Them

The governing principle: aripiprazole's side-effect profile is its whole selling point, so protect it. Most patients tolerate it well. The complaints that actually drive discontinuation are, in order: akathisia, activation/insomnia, and (less often) modest weight gain. Manage those three well and most patients stay on the drug.

Akathisia: The Signature Liability

This is the side effect that defines aripiprazole management. Akathisia is an inner sense of restlessness with an urge to move, it can be present even when the patient isn't visibly moving, so you have to ask. Rates: ~25% in depression-augmentation trials, ~15-19% in mania trials. It is deeply distressing and independently raises suicide risk, so take it seriously.

Management, in Order

1. Prevent it. A low starting dose and slow titration "dramatically reduce" incidence, this is by far the most effective intervention. Much of the historical akathisia reputation came from starting too high.
2. Reduce the dose (often the fastest fix, since akathisia is dose-related).
3. Benzodiazepine: first-line pharmacotherapy for rapid relief: clonazepam 0.5 mg BID standing ± PRN (supported by small RCTs). Bridges symptom control while you adjust.
4. Propranolol: 20 mg BID-TID, titrated up to ~80-240 mg/day as tolerated (check pulse; hold if under 60 bpm). Switch to extended-release once the effective dose is found.
5. Mirtazapine: low dose (≤15 mg) has RCT support; caution: above 15 mg it can cause akathisia.
6. Do NOT reach for benztropine or other anticholinergics, they do not treat akathisia (a persistent and harmful misconception). Anticholinergics treat drug-induced parkinsonism, not akathisia.

Activation, Insomnia, and (Less Often) Sedation

Aripiprazole is more likely to activate than sedate, stimulation outnumbers sedation roughly 2:1, and it's worst early.

• Dose in the morning by default.
• Reassure: activation often improves by around week 6 as tolerance develops.
• If insomnia persists, it's reasonable to add short-term sleep support rather than abandon the drug.
• Sedation (roughly 10% at low doses) is the minority experience; if it happens, switch the dose to evening.

Weight and Metabolic Effects

Aripiprazole sits in the low-liability tier with ziprasidone and lurasidone, minimal weight gain and minimal effect on glucose, triglycerides, and cholesterol, largely because it lacks the antihistamine (H1) activity that drives olanzapine's and quetiapine's weight gain. But low is not zero, especially in antipsychotic-naive patients: in VAST-D, 25% gained ≥7% of body weight by 36 weeks (vs 5% on bupropion).

• Track weight early; catch gain in the first 1-2 months.
• Metformin is the best-evidenced agent (superior to topiramate, which carries cognitive and renal-stone costs). Start 500 mg XR with the largest meal, increase to 500 mg BID after a week, target 750-1,000 mg BID. It works best started early, before the weight is on. Metformin also improves A1c, lipids, and insulin sensitivity. Check CMP/creatinine and B12 periodically.
• Diet, exercise, and (if switching from a dirtier agent) recognize that some of the weight burden may have preceded aripiprazole.

Movement Disorders (EPS and Tardive Dyskinesia)

• Acute EPS/parkinsonism: low risk, one of aripiprazole's advantages (partial agonism preserves nigrostriatal dopamine tone). If it occurs, reduce dose or add benztropine 0.5-2 mg (parkinsonism only, not akathisia).
• Tardive dyskinesia: the class risk is ~3.9%/year (~5%/year in the elderly), and TD has been reported even at 2 mg. It is not zero, requires informed consent, and demands twice-yearly AIMS exams. If TD emerges, options include dose reduction, switching, or a VMAT2 inhibitor (valbenazine, deutetrabenazine).

Prolactin: The Paradox

Uniquely among antipsychotics, aripiprazole tends to lower prolactin at therapeutic doses, because of its dopamine-agonist activity. This is a feature, not a bug: adding aripiprazole 5 mg is the go-to strategy to correct hyperprolactinemia caused by another antipsychotic (e.g., risperidone/paliperidone). At prolactin above 100 ng/mL, aripiprazole 5 mg is often the only effective add-on. At very high doses aripiprazole can begin to raise prolactin, but at ordinary doses hyperprolactinemia is a non-issue.

GI and Anticholinergic

Nausea, constipation, dry mouth are modestly more common than placebo, particularly early. Usually mild and self-limited; standard measures (hydration, fiber, bowel regimen if needed) suffice. Aripiprazole's anticholinergic burden is low.

Cognitive Dulling

Some patients report feeling "cloudy-headed," more so at higher doses (where the drug behaves more like a D2 antagonist). If a patient complains of brain fog, lower the dose, this often resolves it and is another argument for staying at the low end.

The Rare-but-Serious

• Neuroleptic malignant syndrome (NMS): rare, class-wide, fever, rigidity, altered mental status, autonomic instability, elevated CK. Stop the drug; supportive care; consider dantrolene/bromocriptine. Higher risk and higher fatality in intellectually disabled patients.
• Impulse-control behaviors: a distinctive, dopamine-agonist-related effect, pathological gambling, compulsive shopping, hypersexuality, binge eating. Ask about it; it resolves with dose reduction or discontinuation. Warn patients up front.
• Seizure threshold: modestly lowered (class effect); relevant in patients with a seizure history.

Part 6: Overdose, Toxicity, and Boxed Warnings

Overdose and Toxicity

Aripiprazole is comparatively safe in overdose, far safer than lithium or TCAs. There is no specific antidote; management is supportive: airway protection, cardiac monitoring, IV fluids for hypotension, and treatment of agitation. Its long half-life means effects (and any sedation or tachycardia) can be prolonged. Serious cardiotoxicity is uncommon given the minimal QT effect.

Other Class Safety Points

• NMS (see Part 5).
• Orthostatic hypotension: modest alpha-1 effect, more relevant in the elderly and with rapid titration.

Part 7: Drug Interactions

Aripiprazole is a substrate of CYP3A4 and CYP2D6, and its long half-life makes interactions matter more than you'd expect: an inhibitor doesn't just raise the level, it makes an already-long-acting drug "ultra-long-lasting."

The Two Adjustments You Actually Need to Remember

Practical Management

• When starting a strong inhibitor in a patient already on aripiprazole, cut the dose promptly, CYP inhibition is immediate, but the long half-life means the level keeps climbing for days.
• Sustained interactions require attention even with the LAI formulations; the label carries specific dose adjustments for LAIs used with strong 2D6/3A4 inhibitors or inducers for more than 14 days.

What It Does NOT Meaningfully Interact With

• Most SSRIs/SNRIs other than the strong 2D6 inhibitors (sertraline, escitalopram, venlafaxine, duloxetine are generally fine).
• Lithium and valproate (commonly co-prescribed as adjunct in bipolar).
• Pharmacodynamically: watch additive sedation with other CNS depressants and additive orthostasis with antihypertensives, but these are minor with aripiprazole.

Part 8: Special Populations

Pregnancy

Among the atypicals, aripiprazole has accumulating reassuring data and is generally considered one of the reasonable options when an antipsychotic is needed in pregnancy. There is no clear signal for major malformations in the available cohorts, though data remain more limited than for older agents. As with all antipsychotics:

• Weigh the substantial risk of untreated psychotic or bipolar illness (relapse, self-harm, poor prenatal care) against drug risk, often the balance favors continuing.
• Third-trimester exposure carries a class risk of neonatal extrapyramidal signs and withdrawal (agitation, feeding difficulty, respiratory issues); coordinate with OB and pediatrics.
• Manage as a multidisciplinary decision; use the lowest effective dose.

Lactation

Aripiprazole passes into breast milk in small amounts. A concern specific to aripiprazole is that, as a dopamine agonist, it can suppress prolactin and thereby impair lactation/milk supply. If a mother chooses to breastfeed, monitor the infant for sedation and poor feeding, and monitor milk supply. Decisions should be individualized with pediatrics.

Elderly

• Not for dementia-related psychosis (boxed warning).
• Otherwise, aripiprazole is one of the preferred agents in older adults for its low anticholinergic burden, low orthostasis relative to clozapine/quetiapine, and metabolic friendliness.
• Start low, go slow: titrate weekly rather than daily.
• TD risk is higher (~5%/year); do the AIMS.
• In VAST-D/PROSPECT data, aripiprazole augmentation carried a lower fall risk than bupropion in older depressed patients, a point in its favor.

Renal and Hepatic Impairment

Aripiprazole is hepatically metabolized (CYP3A4/2D6) with minimal renal excretion. No dose adjustment is required for renal impairment, and generally none for mild-to-moderate hepatic impairment. Use standard caution in severe hepatic disease.

CYP2D6 Poor Metabolizers

Reduce the initial dose to 50% of usual (FDA label), then titrate to response. Poor metabolizers achieve higher levels and are more prone to dose-related side effects, including akathisia.

Children and Adolescents

• FDA-approved: schizophrenia (13-17), bipolar mania (10+), autism irritability (6-17), Tourette's (6-18).
• Youth are more metabolically vulnerable, monitor weight, glucose, and lipids closely even though aripiprazole is comparatively clean.
• Start low; for autism irritability, address non-pharmacologic triggers and milder options first, the metabolic and neurologic risks are real even for a "clean" agent.

Part 9: Discontinuation and Switching

Aripiprazole does not produce a lithium-style rebound catastrophe, but two discontinuation phenomena deserve respect.

Taper, Don't Stop Abruptly

• A reasonable taper is over 2-6 weeks; longer for patients on high doses or with a history of severe/recurrent episodes.
• Abrupt cessation risks withdrawal-emergent dyskinesia (choreiform movements, peaking 1-4 weeks after stopping) and dopamine-supersensitivity/rebound psychosis from D2 upregulation during chronic exposure. A slow taper mitigates both.
• Because of the ~75-hour half-life, aripiprazole self-tapers somewhat on washout, more forgiving than short-acting agents, but a deliberate taper is still preferred.

Switching TO Aripiprazole Is Where People Get Burned

• Cross-titrating from another antipsychotic to aripiprazole can trigger psychotic exacerbation: in one analysis, 27% had a meaningful PANSS worsening within 28 days, 62% of those within the first week. Higher risk with high baseline antipsychotic doses and prior first-generation use.
• The mechanism: aripiprazole's partial agonism means it occupies D2 receptors but provides only partial blockade; if you yank a full antagonist too fast, the relative "dopamine surge" at supersensitive receptors can flare psychosis.

Part 10: Aripiprazole vs the Alternatives

The class truth (from CATIE and beyond): all atypicals are roughly equally effective for psychosis; you choose by side-effect liability, cost, and patient factors. Aripiprazole's niche is tolerability.

So when do you actually pick aripiprazole? When tolerability is the priority: the metabolically vulnerable patient, the one who can't tolerate prolactin elevation or sedation, the depressed patient needing augmentation, the young first-episode patient in whom you want a clean start, or as an add-on to a dirtier antipsychotic to rescue metabolic or prolactin side effects.

Mechanism: The Short Version

Aripiprazole is a partial agonist at the dopamine D2 receptor, the property that distinguishes it from every older atypical, which are pure D2 antagonists. A partial agonist binds D2 tightly but delivers only a fraction of dopamine's intrinsic activity. The consequence is context-dependent "dopamine stabilization":

• Where dopamine is excessive (mesolimbic pathway, positive psychotic symptoms), aripiprazole competes it off the receptor and functions as a net antagonist, treating psychosis.
• Where dopamine is needed (nigrostriatal pathway, movement), aripiprazole provides enough intrinsic activity to preserve tone, explaining the low EPS/TD risk.
• In the tuberoinfundibular pathway (prolactin control), the agonist activity suppresses prolactin, explaining the paradoxical prolactin-lowering effect.

It is also a partial agonist at 5-HT1A (buspirone-like, plausibly contributing to anxiolytic/antidepressant effects) and an antagonist at 5-HT2A. Its long half-life (~75 h; active metabolite ~94 h) makes it a smooth, forgiving once-daily drug and the natural backbone for long-acting injectables.

The elegant mechanism was oversold for efficacy, it is not superior for psychosis or negative symptoms. But it is a completely satisfying explanation for aripiprazole's real advantage: a clean side-effect profile.

Bedside Cheat Sheet